Overview

• The company plans to replace its Nasdaq ADRs with a direct listing of ordinary shares on the New York Stock Exchange to create a harmonised global listing.
• Following implementation, investors would be able to trade the same ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE.
• A general meeting on 3 November 2025 will consider the plan, and AstraZeneca has published a circular and filed related documents to the UK National Storage Mechanism.
• AstraZeneca states it will remain listed in London and Stockholm, headquartered and tax resident in the UK, and subject to UK corporate governance, including FTSE 100 inclusion.
• Leadership says the change is intended to reach a broader pool of US biopharma investors, with context that the US is its largest market and reports cite a $50 billion five‑year US investment plan.